Doseology Sciences Stock Net Income
| DOSEF Stock | USD 0.05 0.00 0.00% |
Fundamental analysis of Doseology Sciences allows traders to better anticipate movements in Doseology Sciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
Doseology |
Doseology Sciences OTC Stock Net Income Analysis
Doseology Sciences' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Doseology Sciences Net Income | (1.94 M) |
Most of Doseology Sciences' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Doseology Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Doseology Sciences reported net income of (1.94 Million). This is 100.57% lower than that of the Healthcare sector and 102.77% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.34% higher than that of the company.
Doseology Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Doseology Sciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Doseology Sciences could also be used in its relative valuation, which is a method of valuing Doseology Sciences by comparing valuation metrics of similar companies.Doseology Sciences is currently under evaluation in net income category among its peers.
Doseology Fundamentals
| Current Valuation | 430.56 K | |||
| Shares Outstanding | 41.1 M | |||
| Shares Owned By Insiders | 17.78 % | |||
| Price To Book | 0.49 X | |||
| Price To Sales | 61.66 X | |||
| Revenue | 16.05 K | |||
| EBITDA | (1.72 M) | |||
| Net Income | (1.94 M) | |||
| Cash Flow From Operations | (1.71 M) | |||
| Market Capitalization | 4.11 M | |||
| Total Asset | 3.87 M | |||
| Net Asset | 3.87 M |
About Doseology Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Doseology Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Doseology Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Doseology Sciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Doseology OTC Stock
Doseology Sciences financial ratios help investors to determine whether Doseology OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Doseology with respect to the benefits of owning Doseology Sciences security.